• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PARP 抑制剂在卵巢癌中的应用：开拓与变革之旅。

PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.

机构信息

Division of Gynecologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston Massachusetts.

出版信息

Clin Cancer Res. 2018 Sep 1;24(17):4062-4065. doi: 10.1158/1078-0432.CCR-18-1314. Epub 2018 Jun 5.

DOI:10.1158/1078-0432.CCR-18-1314
PMID:29871906
Abstract

PARP inhibitors have transformed treatment for ovarian cancer, a cancer notable for homologous recombination (HR) deficiencies and aberrant DNA repair, especially in the high-grade serous subtype. PARP inhibitors are now approved for recurrent ovarian cancer as maintenance following response to platinum chemotherapy and -mutated (m) cancer treatment. .

摘要

聚腺苷二磷酸核糖聚合酶抑制剂改变了卵巢癌的治疗方式，这种癌症以同源重组（HR）缺陷和异常的 DNA 修复为特征，尤其是在高级别浆液性亚型中。PARP 抑制剂现获准用于铂类化疗反应后的维持治疗以及治疗-突变（m）癌症。

相似文献

1
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.PARP 抑制剂在卵巢癌中的应用：开拓与变革之旅。
Clin Cancer Res. 2018 Sep 1;24(17):4062-4065. doi: 10.1158/1078-0432.CCR-18-1314. Epub 2018 Jun 5.
2
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.奥拉帕利单药维持治疗铂敏感复发性浆液性卵巢癌患者的总生存期：一项随机、安慰剂对照、双盲、2 期临床试验的更新分析。
Lancet Oncol. 2016 Nov;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. Epub 2016 Sep 9.
3
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.美国食品和药物管理局批准概要：尼拉帕利用于铂类化疗后缓解的复发性卵巢癌患者的维持治疗。
Clin Cancer Res. 2018 Sep 1;24(17):4066-4071. doi: 10.1158/1078-0432.CCR-18-0042. Epub 2018 Apr 12.
4
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.聚（ADP 核糖）聚合酶抑制剂尼拉帕利：毒性管理。
Gynecol Oncol. 2018 Apr;149(1):214-220. doi: 10.1016/j.ygyno.2018.01.011. Epub 2018 Feb 4.
5
Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.聚（ADP - 核糖）聚合酶抑制剂在高级别浆液性卵巢癌中的临床应用
Oncologist. 2016 May;21(5):586-93. doi: 10.1634/theoncologist.2015-0438. Epub 2016 Mar 28.
6
The DecisionWhich PARP Inhibitor to Use for Whom and When.决策：何时、针对谁使用哪种 PARP 抑制剂。
Clin Cancer Res. 2017 Dec 1;23(23):7155-7157. doi: 10.1158/1078-0432.CCR-17-2186. Epub 2017 Oct 3.
7
The current status of PARP inhibitors in ovarian cancer.PARP抑制剂在卵巢癌中的现状
Tumori. 2016 Oct 13;102(5):433-440. doi: 10.5301/tj.5000558. Epub 2016 Sep 24.
8
[Abnormalities of DNA repair and gynecological cancers].[DNA修复异常与妇科癌症]
Bull Cancer. 2017 Nov;104(11):971-980. doi: 10.1016/j.bulcan.2017.09.007. Epub 2017 Oct 18.
9
Niraparib for the treatment of ovarian cancer.尼拉帕利治疗卵巢癌。
Expert Rev Anticancer Ther. 2018 Aug;18(8):727-733. doi: 10.1080/14737140.2018.1490180. Epub 2018 Jul 2.
10
[PARP INHIBITORS FOR ADJUVANT TREATMENT FOR OVARIAN CANCER].[聚（ADP-核糖）聚合酶抑制剂用于卵巢癌辅助治疗]
Harefuah. 2020 Mar;159(3):175-180.

引用本文的文献

1
Navigating PARP Inhibitor Resistance in Ovarian Cancer: Bridging Mechanistic Insights To Clinical Translation.应对卵巢癌中的PARP抑制剂耐药性：将机制见解与临床转化相联系
Curr Treat Options Oncol. 2025 Aug 19. doi: 10.1007/s11864-025-01347-z.
2
Improving olaparib exposure to optimize adverse effects management.提高奥拉帕利的药物暴露量以优化不良反应管理。
Ther Adv Med Oncol. 2024 Apr 24;16:17588359241248328. doi: 10.1177/17588359241248328. eCollection 2024.
3
Efficacy and Safety of PARP Inhibitor Therapy in Advanced Ovarian Cancer: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.
PARP抑制剂治疗晚期卵巢癌的疗效与安全性：一项随机对照试验的系统评价与网状Meta分析
Curr Comput Aided Drug Des. 2024;20(6):736-751. doi: 10.2174/1573409920666230907093331.
4
Partial response to niraparib in combination with tislelizumab in a patient with metastatic undifferentiated tonsillar carcinoma: a case report and literature review.尼拉帕利联合替雷利珠单抗治疗转移性未分化扁桃体癌患者的部分缓解：一例病例报告及文献综述
Front Oncol. 2023 May 18;13:1078814. doi: 10.3389/fonc.2023.1078814. eCollection 2023.
5
Emerging roles of m6A RNA modification in cancer therapeutic resistance.m6A RNA修饰在癌症治疗耐药中的新作用。
Exp Hematol Oncol. 2023 Feb 21;12(1):21. doi: 10.1186/s40164-023-00386-2.
6
High Expression of in Tumor and Stroma Cells Predicts Different Prognosis and Platinum Resistance in Patients With Advanced Epithelial Ovarian Cancer.肿瘤细胞和基质细胞中 的高表达预示晚期上皮性卵巢癌患者的不同预后和铂耐药性。 （注：原文中“High Expression of in Tumor and Stroma Cells”这里的“ ”部分缺失具体内容）
Front Oncol. 2022 Jul 7;12:931445. doi: 10.3389/fonc.2022.931445. eCollection 2022.
7
New Advances in Targeted Therapy of HER2-Negative Breast Cancer.HER2阴性乳腺癌靶向治疗的新进展
Front Oncol. 2022 Mar 4;12:828438. doi: 10.3389/fonc.2022.828438. eCollection 2022.
8
BRCA1 mutations in high-grade serous ovarian cancer are associated with proteomic changes in DNA repair, splicing, transcription regulation and signaling.BRCA1 突变与高级别浆液性卵巢癌中的 DNA 修复、剪接、转录调控和信号转导相关的蛋白质组变化有关。
Sci Rep. 2022 Mar 15;12(1):4445. doi: 10.1038/s41598-022-08461-0.
9
Angiogenesis as Therapeutic Target in Metastatic Prostate Cancer - Narrowing the Gap Between Bench and Bedside.血管生成作为转移性前列腺癌的治疗靶点——缩小基础研究与临床治疗之间的差距。
Front Immunol. 2022 Feb 10;13:842038. doi: 10.3389/fimmu.2022.842038. eCollection 2022.
10
Characterization of a -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.PARP抑制剂耐药性发展过程中α-沉默高级别浆液性卵巢癌模型的特征分析
NAR Cancer. 2021 Jul 9;3(3):zcab028. doi: 10.1093/narcan/zcab028. eCollection 2021 Sep.